Improving the quality of cancer clinical trials workshop summary /
I tiakina i:
| Ngā kaituhi rangatōpū: | , , |
|---|---|
| Ētahi atu kaituhi: | , |
| Hōputu: | Tāhiko īPukapuka |
| Reo: | Ingarihi |
| I whakaputaina: |
Washington, D.C. :
National Academies Press,
c2008.
|
| Ngā marau: | |
| Urunga tuihono: | An electronic book accessible through the World Wide Web; click to view |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Rārangi ihirangi:
- Introduction
- New clinical trial designs. Phase 0 trials
- Adaptive trial designs
- Targeting multiple pathways with multiple drugs
- Preclinical model systems
- Molecular imaging. Current and developing methods
- Challenges of molecular imaging
- Screening for predictive markers. The challenges of clinical validation
- Bioimaging predictive markers
- Clinical translation
- Panel discussion
- Costs of clinical trials. Regulatory costs
- Patient accrual
- Global outsourcing
- Time is money
- Public-private collaborations
- Regulatory issues. Regulatory barriers to innovation
- Patient advocacy perspective
- Regulation of in vitro diagnostics
- Regulatory issues in improving cancer clinical trials
- Reports from the case study discussion groups. Adaptive trial design
- Phase 0 trials
- Imaging
- Use of proteomics/genomics to assign therapy in lung cancer
- Use of genetics/genomics to assign therapy.